BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-350@pharmaconomics
DTSTAMP:20260707T003631Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:ANAB Phase 2 — dostarlimab (estimated date)
DESCRIPTION:Phase 2 trial results for dostarlimab in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer are due ~ Sep 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/350
URL:https://pharmaconomics.com/e/350
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ANAB catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR